--- title: "The Hong Kong Misfits: Tokenized ETFs, AI Struggles, and Trading Illusions" type: "News" locale: "en" url: "https://longbridge.com/en/news/293093884.md" description: "From tokenized funds pushing boundaries to tech firms playing day trader, the fringes of the Hong Kong market are a chaotic survival game. Here is a sharp look at who is actually building and who is just faking it." datetime: "2026-07-18T09:13:06.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293093884.md) - [en](https://longbridge.com/en/news/293093884.md) - [zh-HK](https://longbridge.com/zh-HK/news/293093884.md) generator: "portal-rs" --- # The Hong Kong Misfits: Tokenized ETFs, AI Struggles, and Trading Illusions If you want to understand the true underbelly of the Hong Kong market, stop staring at the earnings reports of Tencent and Alibaba. Look at this wild grab bag of micro-caps, tech experiments, and tokenized ETFs. It is like watching a chaotic survival game where some companies are genuinely trying to innovate, while others are just spinning their wheels in the capital markets. This is stupid and here's why. Let us start with **Brainhole Technology (2203.HK)**. This so-called semiconductor company made headlines in June 2026 not for a groundbreaking new chip, but for buying up shares of Jiaxin and trading Marvell stock. A tech firm playing day trader with its balance sheet instead of investing in R&D? Good luck with that. Then there is **Changjiu Holdings (6959.HK)**, a vehicle pledge monitoring firm. The SFC called them out for highly concentrated shareholding, and the stock predictably crashed by **66%**. It is a classic insider game that ended in a completely avoidable bloodbath. Meanwhile, **Quantum Thinking (8050.HK)** throws around massive buzzwords like 5G and digital finance security. Sure, their recent revenue surged over **164%** year-over-year, but they are still bleeding net losses. In today's market, top-line growth without bottom-line reality is a story no one wants to hear. Tech is not entirely a wasteland here, but reality bites hard. **METiS Therapeutics (7666.HK)** has a compelling AI drug discovery narrative and even successfully out-licensed its MTS-128 product in July 2026. The market's reaction? The stock plunged over **12%** to a record low. That is what happens when your revenue structure is too thin. The AI label simply cannot save a hemorrhaging balance sheet. In contrast, **Beke Micro (2149.HK)** is quietly designing analog ICs for automotive and industrial automation uses without the ridiculous fanfare. In this noisy sector, putting your head down and actually building a business is a rare quality. If you want real financial innovation, look at the **CSOP HKD Money Market ETF (3053.HK)**. In June 2026, they teamed up with HSBC and OSL to launch a non-listed tokenized class. Bringing on-chain crypto liquidity to traditional yield instruments is a smart, forward-looking move. On the other hand, its sibling, the **CSOP HSCEI Daily 2x Leveraged Product (7288.HK)**, is just a standard leveraged fund—strictly for those who want to gamble on index volatility. Back in the real economy, **China Kepei (1890.HK)** pulled in over **RMB 1.1B** in H1 2026 revenue, up **20.2%**. Net profits slipped by 9.9%, but at least they have real students paying real tuition. Cosmetics maker **Chicmax (2145.HK)** held its own with double-digit growth during the 618 shopping festival, though the sudden exit of an executive director in late June makes you question their stability. Why aren't you moving faster to ensure management transparency? Finally, there is **Shun Ten International (0932.HK)**, pushing dietary supplements while still posting a net loss of around **HKD 26.6M** in FY2026. The losses are narrowing, but this business clearly needs a stronger catalyst. This is the folded reality of the long tail. Do not expect to find the next Big Tech giant hidden in these fringes. But if you have to dig through this pile, stick to the ones with actual cash flow and ignore the storytellers obsessed with financial engineering. My view is clear: stop wasting time on companies that are asleep at the wheel. *This article does not constitute investment advice.* ### Related Stocks - [08050.HK](https://longbridge.com/en/quote/08050.HK.md) - [02203.HK](https://longbridge.com/en/quote/02203.HK.md) - [01890.HK](https://longbridge.com/en/quote/01890.HK.md) - [06959.HK](https://longbridge.com/en/quote/06959.HK.md) - [02149.HK](https://longbridge.com/en/quote/02149.HK.md) - [07666.HK](https://longbridge.com/en/quote/07666.HK.md) - [02145.HK](https://longbridge.com/en/quote/02145.HK.md) ## Related News & Research - [BaTeLab Shareholders Approve Amendments to Articles at 2026 EGM](https://longbridge.com/en/news/296789818.md) - [Metis TechBio set to join Hang Seng Composite Index from Sept. 7, 2026](https://longbridge.com/en/news/296700391.md) - [Shanghai Chicmax Cosmetic schedules board meeting to review interim results](https://longbridge.com/en/news/296109696.md) - [Metis TechBio Co: Revenue up 13,399% and adjusted net loss down 56.4%, with major licensing and IPO milestones](https://longbridge.com/en/news/296891884.md) - [Metis TechBio FY26 H1 loss attributable to owners narrows 20% to RMB 153.21 million; revenue jumps to RMB 154.29 million](https://longbridge.com/en/news/296890992.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**